Participated · Series A · Aug 2026

Founded in 2022 by former Citibank, Deutsche Bank, Kotak and 360 ONE WAM executives, Centricity offers a technology-led wealth management platform that gives advisors and distributors access to mutual funds, insurance, bonds, portfolio management services, alternative investment funds, broking, GIFT City opportunities and offshore investment solutions. Its platform automates portfolio consolidation, reporting, risk analytics and investment monitoring to help advisors and family offices manage multi-product, multi-region portfolios. Three years after founding, Centricity reports over ₹15,000 crore in assets under management, more than 20,000 partners, over 100,000 investors and relationships with more than 250 family offices, with 60% of assets generating recurring revenue. The company says its business grew nearly 200% year-over-year and is on track to surpass ₹150 crore in revenue in FY27. Centricity has expanded internationally via Centricity Global Private Client to serve non-resident Indians and global investors through GIFT City and DIFC offerings and plans to scale its private-banker headcount domestically and for NRI business as part of its growth strategy.

Participated · Series B · Feb 2026

Pandorum Technologies, operating in India and the United States, has built a proprietary platform that integrates biology, engineering and computation to create tunable exosome therapies capable of reprogramming pathological tissue states such as inflammation and fibrosis. Its lead product, Kuragenx, targets ocular surface diseases—including Stevens–Johnson Syndrome and Neurotrophic Keratitis—and has received U.S. FDA Orphan Drug Designation. The company’s broader vision is to scale from single-tissue repair to multi-tissue regeneration, ultimately enabling patients to "heal fast and age slow." To support commercialization, Pandorum has established a distributed manufacturing strategy, working with AGC Biologics in Italy for U.S. and European markets and Nucelion Therapeutics (a Bharat Biotech subsidiary) for Asia-Pacific supply, while evaluating partnerships in the Middle East. Future plans include expanding the platform to treat inflammatory and degenerative conditions affecting the lung, liver and nervous systems. The newly secured US$18 million Series B financing positions the company to advance clinical programs, scale production and enlarge its global footprint.